Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Strata Critical Medical (SRTAW) over the last 7 years, with Q2 2025 value amounting to $9.1 million.

  • Strata Critical Medical's Current Deferred Revenue fell 166.2% to $9.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $9.1 million, marking a year-over-year decrease of 166.2%. This contributed to the annual value of $6.7 million for FY2024, which is 276.11% down from last year.
  • Latest data reveals that Strata Critical Medical reported Current Deferred Revenue of $9.1 million as of Q2 2025, which was down 166.2% from $8.0 million recorded in Q1 2025.
  • In the past 5 years, Strata Critical Medical's Current Deferred Revenue ranged from a high of $10.0 million in Q2 2023 and a low of $4.4 million during Q1 2021
  • Over the past 5 years, Strata Critical Medical's median Current Deferred Revenue value was $6.8 million (recorded in 2022), while the average stood at $7.1 million.
  • In the last 5 years, Strata Critical Medical's Current Deferred Revenue surged by 6141.28% in 2022 and then crashed by 746.95% in 2024.
  • Over the past 5 years, Strata Critical Medical's Current Deferred Revenue (Quarter) stood at $6.0 million in 2021, then increased by 12.27% to $6.7 million in 2022, then rose by 2.03% to $6.8 million in 2023, then dropped by 2.76% to $6.7 million in 2024, then surged by 36.9% to $9.1 million in 2025.
  • Its Current Deferred Revenue was $9.1 million in Q2 2025, compared to $8.0 million in Q1 2025 and $6.7 million in Q4 2024.